Ysine Krich Ctermirius

EAEEDQOLCCLCVKTTSQVRPR HITSLE VI K AG HCPTAQLtATLKNQRKICLDLQAPLY

FIGURE 6.4 Primary and secondary structure of PF4 in relation to HIT neoepitopes. (Top) 3D representation of the PF4 tetramer, indicating two neoepitope sites (per monomer). The "ring of positive charge" is formed by lysine residues in the C-terminus (light blue) and other lysine and arginine residues (dark blue). (Bottom) The linear sequence of the 70-amino acid polypeptide of a single PF4 molecule is shown. Abbreviation: PF4, platelet factor 4.

FIGURE 6.4 Primary and secondary structure of PF4 in relation to HIT neoepitopes. (Top) 3D representation of the PF4 tetramer, indicating two neoepitope sites (per monomer). The "ring of positive charge" is formed by lysine residues in the C-terminus (light blue) and other lysine and arginine residues (dark blue). (Bottom) The linear sequence of the 70-amino acid polypeptide of a single PF4 molecule is shown. Abbreviation: PF4, platelet factor 4.

CD40 ^ CD154 I Fc receptor f TF X platelet microparticles

FIGURE 6.6 Proposed model of pathogenesis in HIT and thrombosis. PF4 is postulated to be both the target for the antibody (when complexed with heparin) and a modulator of T-cell responsiveness (see text for additional details). Abbreviations: APC, antigen-presenting cell; GAG, glycosami-noglycan; HIT, heparin-induced thrombocytopenia; MHC, major histocompatibility complex; PF4, platelet factor 4; TCR, T-cell receptor; Tr, T regulatory; TF, tissue factor.

0 0

Post a comment